At the molecular level, mitigating IL-1β signaling would prevent the oncogenic activation of the alternative pathway of NF-κB signaling in lung cancer cells, impairing in this way the cascade initiated by KRAS mutant tumor cells [25]. The gene discussed is KRAS; the disease is lung carcinoma.